NasdaqGM:ADMS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States.


Snowflake Analysis

Slightly overvalued with limited growth.

Share Price & News

How has Adamas Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ADMS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-4.3%

ADMS

0.07%

US Biotechs

2.9%

US Market


1 Year Return

-43.5%

ADMS

23.9%

US Biotechs

8.9%

US Market

Return vs Industry: ADMS underperformed the US Biotechs industry which returned 23.9% over the past year.

Return vs Market: ADMS underperformed the US Market which returned 8.9% over the past year.


Shareholder returns

ADMSIndustryMarket
7 Day-4.3%0.07%2.9%
30 Day-20.7%4.8%10.6%
90 Day-32.1%10.5%5.1%
1 Year-43.5%-43.5%25.1%23.9%11.4%8.9%
3 Year-85.0%-85.0%32.9%28.5%34.3%25.4%
5 Year-86.4%-86.4%-4.4%-10.0%60.7%42.7%

Price Volatility Vs. Market

How volatile is Adamas Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Adamas Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ADMS ($2.64) is trading below our estimate of fair value ($6.34)

Significantly Below Fair Value: ADMS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ADMS is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ADMS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ADMS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ADMS has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.


Next Steps

Future Growth

How is Adamas Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

51.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ADMS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ADMS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ADMS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ADMS's revenue (21.1% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: ADMS's revenue (21.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ADMS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Adamas Pharmaceuticals performed over the past 5 years?

-27.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ADMS is currently unprofitable.

Growing Profit Margin: ADMS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ADMS is unprofitable, and losses have increased over the past 5 years at a rate of -27.1% per year.

Accelerating Growth: Unable to compare ADMS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ADMS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: ADMS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Adamas Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: ADMS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: ADMS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: ADMS has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: ADMS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ADMS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ADMS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Adamas Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ADMS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ADMS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ADMS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ADMS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ADMS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Neil McFarlane (46yo)

0.75

Tenure

US$2,523,429

Compensation

Mr. Neil F. Mcfarlane serves as Chief Executive Officer and Director of Adamas Pharmaceuticals, Inc. since September 16, 2019. Mr. Mcfarlane served as Chief Operating Officer of Retrophin, Inc. since Augus ...


CEO Compensation Analysis

Compensation vs Market: Neil's total compensation ($USD2.52M) is above average for companies of similar size in the US market ($USD577.87K).

Compensation vs Earnings: Insufficient data to compare Neil's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Neil McFarlane
CEO & Director0.75yrUS$2.52mno data
Christopher Prentiss
Chief Financial Officer0.58yrUS$1.09m0.046% $34.5k
Vijay Shreedhar
Chief Commercial Officer1.08yrsUS$1.40m0.0089% $6.6k
Sarah Mathieson
Head of Corporate Communications1.33yrsno datano data
Dean Hart
Senior Vice President of Salesno datano datano data
Eric Schlezinger
Head of Human Resources0.58yrno datano data
Melissa Masterson
Senior Vice President of Commercial Operations & Market Accessno datano datano data

0.8yrs

Average Tenure

47yo

Average Age

Experienced Management: ADMS's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Neil McFarlane
CEO & Director0.75yrUS$2.52mno data
William Ericson
Independent Director15.42yrsUS$84.71kno data
Martha Demski
Independent Director6.25yrsUS$94.71k0.046% $34.3k
David Mahoney
Chairman & Lead Independent Director0.75yrUS$264.88k0.21% $157.8k
Ivan Lieberburg
Independent Director16.42yrsUS$67.71k0.23% $169.0k
Jeffrey Cummings
Scientific & Clinical Advisorno datano datano data
Arnold Monto
Member of Influenza Advisory Boardno datano datano data
Matthew Stern
Scientific & Clinical Advisorno datano datano data
Martin Farlow
Member of CNS Advisory Boardno datano datano data
Alan Perelson
Member of Influenza Advisory Boardno datano datano data

6.3yrs

Average Tenure

65.5yo

Average Age

Experienced Board: ADMS's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.3%.


Top Shareholders

Company Information

Adamas Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Adamas Pharmaceuticals, Inc.
  • Ticker: ADMS
  • Exchange: NasdaqGM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$74.338m
  • Shares outstanding: 28.16m
  • Website: https://www.adamaspharma.com

Number of Employees


Location

  • Adamas Pharmaceuticals, Inc.
  • 1900 Powell Street
  • Suite 1000
  • EmeryVille
  • California
  • 94608
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ADMSNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDApr 2014
136DB (Deutsche Boerse AG)YesCommon StockDEEURApr 2014

Biography

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer’s type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/05 05:21
End of Day Share Price2020/06/04 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.